Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.

GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.

Twist-1 is being explored as a promising early-stage hair loss treatment, while Scube-3's effect on Twist-1 in breast cancer cells raises concerns about its use for hair loss. The conversation discusses the potential differences in protein effects across various cell types.

A 42-year-old user shared positive results from using oral and topical Minoxidil, Finasteride, and weekly dermarolling for hair regrowth over three months. The community responded positively, noting significant progress and discussing treatment details and concerns.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

The user switched from oral minoxidil to topical minoxidil and added JXL-069/PP405-3HP, along with topical dutasteride, melatonin, and tretinoin. They also use low-level laser therapy (LLLT) but doubt its effectiveness.

ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.

The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.

The conversation is about a user expressing concerns over the safety of a new drug called Pyrilutamide (also known as KX-826) for hair loss. The user will only trust the drug if it's permitted by EU regulations and sold by a reputable company.

Pyrilutamide's inconsistent trial results, with phase II showing positive hair growth and phase III failing to show significant gains, possibly due to COVID-related disruptions. Users discuss modest results from kx-826 treatment.

The conversation is about hair regrowth progress using dutasteride and minoxidil. Users discuss their experiences, progress, and side effects with these treatments.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

The conversation discusses using microneedling with copper peptides, specifically GHK-Cu, for hair loss treatment. Some users combine it with minoxidil and topical finasteride, applying peptides either topically or through injection.

A user is considering trying Man Matters' new Minoxifin Advanced, which combines minoxidil and finasteride with "cetosomal technology" for better absorption, but is unsure if it's worth the higher price. Another user criticizes the brand, but the original poster finds it suitable for their scalp without irritation.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

A user shared progress pictures after three months of using 5mg oral minoxidil and 0.5mg oral finasteride, showing significant hair regrowth following a hair transplant. Other users praised the results, discussed similar experiences, and expressed interest in trying oral minoxidil.

The conversation is about finding providers for Dutasteride Mesotherapy in the US, which is more common in Europe. The user is asking if any mesotherapy/PRP clinic could offer it if they provide the Dutasteride.

Users discussed the effectiveness of Everychem's solution, similar to PP405, with some reporting improved hair thickness and new growth. Concerns were raised about safety and the legitimacy of the product, with some users advising against purchasing research chemicals.

The conversation is about hair loss treatment progress using oral finasteride, topical minoxidil, and microneedling. Users discuss experiencing shedding phases and the importance of trusting the process for hair regrowth.

People are pessimistic about PP405, believed to be Jxl-069, due to doubts about its effectiveness and delivery method. Some think it doesn't work, while others blame the vehicle used for application.

The conversation discusses using a dermapen for microneedling to treat hair loss, with specific mention of using Minoxidil, Finasteride, Dutasteride, RU58841, KX-826, and other topicals. The user experienced side effects like palpitations and itching after microneedling and applying these treatments.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

The user shared a 2-month update after receiving 2023 hair grafts, noting improvements in hair thickness, density, and color after starting finasteride and minoxidil. They are still in the early recovery phase.

The user is treating alopecia areata with 1.25mg oral minoxidil daily and topical mometasone furoate, considering increasing the dose or adding finasteride, though finasteride is not typically used for this condition. A gluten-free diet is suggested, and alternatives like Olumiant are mentioned.

The conversation discusses hair regrowth using minoxidil and dutasteride, with users sharing their experiences and results. Some users report improvements, while others mention side effects like low libido and erectile dysfunction.